Fibrosprogress

Fibrosprogress is a term occasionally used in medical literature to describe the ongoing, dynamic progression of fibrotic remodeling in tissues after chronic injury or inflammation. It emphasizes the temporal aspect of fibrosis, recognizing that fibrotic burden can increase over time even when initial injury appears controlled. The term is not part of a formal diagnostic taxonomy and is not universally adopted in clinical guidelines; it is often used in discussions of disease trajectory and research contexts rather than as a standalone diagnosis.

In practice, fibrosprogress can pertain to progressive fibrosis in multiple organs, including the lungs, liver, kidneys, and heart. Presentations depend on the affected tissue and may include declining organ function, reduced exercise tolerance, abnormal imaging findings, and rising biomarkers of extracellular matrix turnover. The concept highlights that fibrosis may advance through ongoing activation of myofibroblasts, persistent deposition of collagen and other matrix components, and maladaptive tissue remodeling driven by pathways such as TGF-beta and inflammatory mediators.

Assessment relies on serial evaluations to capture progression. Imaging modalities like high-resolution CT for lungs or elastography-based techniques for other organs, along with functional testing and laboratory biomarkers of collagen turnover, help track changes over time. Management focuses on treating the underlying cause, slowing fibrotic progression with disease-specific or antifibrotic therapies when available, and providing supportive care. The term is mainly a heuristic in research and clinical discussions to frame the kinetics of fibrosis rather than a distinct, universally defined disease entity. Further study aims to clarify its applicability across diseases and to refine endpoints for progression.